Study to Evaluate HER2-neu Expression in Different Histopathological Grades of Prostatic Carcinoma in a Tertiary Care Centre, Bareilly
Introduction: Prostate cancer is the second most common neoplasm among men around the world. Two routinely used immunocytochemical markers for prostatic epithelium are Prostatic Acid Phosphatase (PAP) and Prostatic Specific Antigen (PSA). Various other markers like Prostate-Specific Membrane An...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2020-12-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/14358/45082_CE(Ra1)_P(AK)_PF1_(AD_OM)_PN(SL).pdf |
| _version_ | 1818907227695611904 |
|---|---|
| author | SURBHI BANSAL HEMA PANT TANU AGRAWAL PIYUSH KUMAR PRADEEP MEHDIRATTA |
| author_facet | SURBHI BANSAL HEMA PANT TANU AGRAWAL PIYUSH KUMAR PRADEEP MEHDIRATTA |
| author_sort | SURBHI BANSAL |
| collection | DOAJ |
| description | Introduction: Prostate cancer is the second most common
neoplasm among men around the world. Two routinely used
immunocytochemical markers for prostatic epithelium are
Prostatic Acid Phosphatase (PAP) and Prostatic Specific Antigen
(PSA). Various other markers like Prostate-Specific Membrane
Antigen (PSMA), androgen and progesterone receptors, HER2-
neu, low molecular weight keratin, etc., are also used. HER2-neu
overexpression has been implicated in tumorigenesis and has
been correlated with a poor prognosis for patients with breast
cancer, ovarian cancer, and gastric cancer. Use of Trastuzumab
for the treatment of breast carcinoma has improved prognosis
in HER2-neu positive cases. Recent studies have suggested
the correlation of HER2-neu overexpression with higher grades
of prostate cancer.
Aim: To study HER2-neu expression in different histopathological
grades of prostatic carcinoma.
Materials and Methods: A prospective study was carried out
on 41 histopathologically proven cases of prostatic carcinoma
in Pathology Department of SRMSIMS, Bareilly over a period
of one year and six months (November 2017 to April 2019).
Gleason grading and HER2-neu Immunohistochemistry was
applied on every case and then correlated. Statistical tests were
applied, statistical software Statistical Package for the Social
Sciences (SPSS) version 21.
Results: A 92.7% (38/41) cases were reported as Prostatic
Adenocarcinoma of Non-Mucinous type. Total of 42.5% (17/40)
were grouped under Grade group 5, 27.5% (11/40) cases
under Grade group 3 and 10% (4/40) under Grade groups 1,2
and 4 each. Out of total, 14.6% (6/41) cases were considered
as positive and 80.5% (33/41) cases were considered as
negative for HER2-neu expression and 4.9% (2/41) cases were
considered as equivocal (Fluorescence In Situ Hybridization
(FISH) conformation required). In cases with positive HER2-neu
expression, mean group grade was calculated to be 4.83±0.40
and in patients with negative HER2-neu expression, it was
3.38±1.40 (it was calculated to find correlation between group
grade and HER2-neu expression). There was a significant
statistical difference (p=0.00003668) found between the Gleason
Group Grade in HER2-neu positive and negative patients as
HER2-neu positivity is seen in higher group grades. One case
was reported as neuroendocrine carcinoma in which Gleason
grading was not done.
Conclusion: Compared to low Gleason Group Grade carcinoma,
higher percentage of HER2-neu expression was seen in high
Gleason Group grade carcinoma. |
| first_indexed | 2024-12-19T21:51:46Z |
| format | Article |
| id | doaj.art-09ca892c43e846f5bea2932b7cb66ad1 |
| institution | Directory Open Access Journal |
| issn | 2249-782X 0973-709X |
| language | English |
| last_indexed | 2024-12-19T21:51:46Z |
| publishDate | 2020-12-01 |
| publisher | JCDR Research and Publications Private Limited |
| record_format | Article |
| series | Journal of Clinical and Diagnostic Research |
| spelling | doaj.art-09ca892c43e846f5bea2932b7cb66ad12022-12-21T20:04:22ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2020-12-011412EC09EC1310.7860/JCDR/2020/45082.14358Study to Evaluate HER2-neu Expression in Different Histopathological Grades of Prostatic Carcinoma in a Tertiary Care Centre, BareillySURBHI BANSAL0HEMA PANT1TANU AGRAWAL2PIYUSH KUMAR3PRADEEP MEHDIRATTA4Junior Resident, Department of Pathology, Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly, Uttar Pradesh, India.Professor, Department of Pathology, Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly, Uttar Pradesh, India.Professor and Head, Department of Pathology, Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly, Uttar Pradesh, India.Professor and Head, Department of Radiotherapy, Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly, Uttar Pradesh, India.Associate Professor, Department of Urology, Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly, Uttar Pradesh, India.Introduction: Prostate cancer is the second most common neoplasm among men around the world. Two routinely used immunocytochemical markers for prostatic epithelium are Prostatic Acid Phosphatase (PAP) and Prostatic Specific Antigen (PSA). Various other markers like Prostate-Specific Membrane Antigen (PSMA), androgen and progesterone receptors, HER2- neu, low molecular weight keratin, etc., are also used. HER2-neu overexpression has been implicated in tumorigenesis and has been correlated with a poor prognosis for patients with breast cancer, ovarian cancer, and gastric cancer. Use of Trastuzumab for the treatment of breast carcinoma has improved prognosis in HER2-neu positive cases. Recent studies have suggested the correlation of HER2-neu overexpression with higher grades of prostate cancer. Aim: To study HER2-neu expression in different histopathological grades of prostatic carcinoma. Materials and Methods: A prospective study was carried out on 41 histopathologically proven cases of prostatic carcinoma in Pathology Department of SRMSIMS, Bareilly over a period of one year and six months (November 2017 to April 2019). Gleason grading and HER2-neu Immunohistochemistry was applied on every case and then correlated. Statistical tests were applied, statistical software Statistical Package for the Social Sciences (SPSS) version 21. Results: A 92.7% (38/41) cases were reported as Prostatic Adenocarcinoma of Non-Mucinous type. Total of 42.5% (17/40) were grouped under Grade group 5, 27.5% (11/40) cases under Grade group 3 and 10% (4/40) under Grade groups 1,2 and 4 each. Out of total, 14.6% (6/41) cases were considered as positive and 80.5% (33/41) cases were considered as negative for HER2-neu expression and 4.9% (2/41) cases were considered as equivocal (Fluorescence In Situ Hybridization (FISH) conformation required). In cases with positive HER2-neu expression, mean group grade was calculated to be 4.83±0.40 and in patients with negative HER2-neu expression, it was 3.38±1.40 (it was calculated to find correlation between group grade and HER2-neu expression). There was a significant statistical difference (p=0.00003668) found between the Gleason Group Grade in HER2-neu positive and negative patients as HER2-neu positivity is seen in higher group grades. One case was reported as neuroendocrine carcinoma in which Gleason grading was not done. Conclusion: Compared to low Gleason Group Grade carcinoma, higher percentage of HER2-neu expression was seen in high Gleason Group grade carcinoma.https://jcdr.net/articles/PDF/14358/45082_CE(Ra1)_P(AK)_PF1_(AD_OM)_PN(SL).pdfprostatic adenocarcinomaprostatic specific antigentrastuzumab |
| spellingShingle | SURBHI BANSAL HEMA PANT TANU AGRAWAL PIYUSH KUMAR PRADEEP MEHDIRATTA Study to Evaluate HER2-neu Expression in Different Histopathological Grades of Prostatic Carcinoma in a Tertiary Care Centre, Bareilly Journal of Clinical and Diagnostic Research prostatic adenocarcinoma prostatic specific antigen trastuzumab |
| title | Study to Evaluate HER2-neu Expression in Different Histopathological Grades of Prostatic Carcinoma in a Tertiary Care Centre, Bareilly |
| title_full | Study to Evaluate HER2-neu Expression in Different Histopathological Grades of Prostatic Carcinoma in a Tertiary Care Centre, Bareilly |
| title_fullStr | Study to Evaluate HER2-neu Expression in Different Histopathological Grades of Prostatic Carcinoma in a Tertiary Care Centre, Bareilly |
| title_full_unstemmed | Study to Evaluate HER2-neu Expression in Different Histopathological Grades of Prostatic Carcinoma in a Tertiary Care Centre, Bareilly |
| title_short | Study to Evaluate HER2-neu Expression in Different Histopathological Grades of Prostatic Carcinoma in a Tertiary Care Centre, Bareilly |
| title_sort | study to evaluate her2 neu expression in different histopathological grades of prostatic carcinoma in a tertiary care centre bareilly |
| topic | prostatic adenocarcinoma prostatic specific antigen trastuzumab |
| url | https://jcdr.net/articles/PDF/14358/45082_CE(Ra1)_P(AK)_PF1_(AD_OM)_PN(SL).pdf |
| work_keys_str_mv | AT surbhibansal studytoevaluateher2neuexpressionindifferenthistopathologicalgradesofprostaticcarcinomainatertiarycarecentrebareilly AT hemapant studytoevaluateher2neuexpressionindifferenthistopathologicalgradesofprostaticcarcinomainatertiarycarecentrebareilly AT tanuagrawal studytoevaluateher2neuexpressionindifferenthistopathologicalgradesofprostaticcarcinomainatertiarycarecentrebareilly AT piyushkumar studytoevaluateher2neuexpressionindifferenthistopathologicalgradesofprostaticcarcinomainatertiarycarecentrebareilly AT pradeepmehdiratta studytoevaluateher2neuexpressionindifferenthistopathologicalgradesofprostaticcarcinomainatertiarycarecentrebareilly |